Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
GBT's Cash-to-Debt is ranked higher than
64% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. GBT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GBT' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
GBT's Interest Coverage is ranked higher than
54% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GBT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GBT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 59.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -46.55
GBT's ROE % is ranked lower than
54% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. GBT: -46.55 )
Ranked among companies with meaningful ROE % only.
GBT' s ROE % Range Over the Past 10 Years
Min: -110.51  Med: -80.47 Max: -46.55
Current: -46.55
-110.51
-46.55
ROA % -43.21
GBT's ROA % is ranked lower than
58% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. GBT: -43.21 )
Ranked among companies with meaningful ROA % only.
GBT' s ROA % Range Over the Past 10 Years
Min: -293.52  Med: -56.87 Max: -43.21
Current: -43.21
-293.52
-43.21
ROC (Joel Greenblatt) % -3459.26
GBT's ROC (Joel Greenblatt) % is ranked lower than
75% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. GBT: -3459.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GBT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3666.83  Med: -1588.74 Max: -662
Current: -3459.26
-3666.83
-662
GuruFocus has detected 4 Warning Signs with Global Blood Therapeutics Inc $GBT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GBT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GBT Guru Trades in Q1 2016

Steven Cohen 112,300 sh (New)
George Soros Sold Out
Louis Moore Bacon Sold Out
» More
Q2 2016

GBT Guru Trades in Q2 2016

Paul Tudor Jones 26,243 sh (New)
Steven Cohen Sold Out
» More
Q3 2016

GBT Guru Trades in Q3 2016

Jim Simons 101,200 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

GBT Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2834
Compare:NYSE:CBM, OTCPK:DBVTF, NAS:AAAP, OTCPK:MPSYY, NAS:HALO, NAS:ONCE, NAS:SRPT, NAS:TBPH, NAS:ARRY, NAS:FGEN, OTCPK:SOLTF, NAS:LXRX, NYSE:AXON, NAS:PBYI, NAS:BPMC, NAS:PRTA, NAS:BGNE, NAS:DERM, NAS:INVA, OTCPK:GENSF » details
Traded in other countries:G5B.Germany,
Global Blood Therapeutics Inc is a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders.

Global Blood Therapeutics Inc was incorporated under the laws of the State of Delaware in February 2011. It is a biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It is developing its initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease, or SCD, and are currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. SCD is a disease marked by severe pain "crises," recurrent hospitalizations, multi-organ damage, and early mortality. GBT440 is a novel hemoglobin modifier that binds to hemoglobin molecules. Oxyhemoglobin, or hemoglobin in the oxygenated state, is a potent inhibitor of HbS polymerization. Its patent portfolio includes three issued U.S. patents, two allowed U.S. patent applications, and several U.S. and foreign patent applications in the early stages of prosecution.

Ratios

vs
industry
vs
history
PB Ratio 6.75
GBT's PB Ratio is ranked lower than
74% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. GBT: 6.75 )
Ranked among companies with meaningful PB Ratio only.
GBT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.28
Current: 6.75
0
7.28
Current Ratio 9.65
GBT's Current Ratio is ranked higher than
79% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GBT: 9.65 )
Ranked among companies with meaningful Current Ratio only.
GBT' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 12.6 Max: 21.12
Current: 9.65
0.99
21.12
Quick Ratio 9.65
GBT's Quick Ratio is ranked higher than
79% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GBT: 9.65 )
Ranked among companies with meaningful Quick Ratio only.
GBT' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 12.6 Max: 21.12
Current: 9.65
0.99
21.12

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.54
GBT's Price-to-Net-Cash is ranked lower than
66% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. GBT: 9.54 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GBT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.66  Med: 5.29 Max: 10.32
Current: 9.54
3.66
10.32
Price-to-Net-Current-Asset-Value 9.35
GBT's Price-to-Net-Current-Asset-Value is ranked lower than
71% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. GBT: 9.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GBT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.59  Med: 5.22 Max: 10.11
Current: 9.35
3.59
10.11
Price-to-Tangible-Book 6.72
GBT's Price-to-Tangible-Book is ranked lower than
68% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. GBT: 6.72 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GBT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.58  Med: 4.66 Max: 7.26
Current: 6.72
2.58
7.26
Earnings Yield (Greenblatt) % -5.56
GBT's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. GBT: -5.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GBT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -266.48  Med: 0 Max: 0
Current: -5.56
-266.48
0

More Statistics

EPS (TTM) $ -2.48
Short Percentage of Float47.86%
52-Week Range $12.24 - 41.15
Shares Outstanding (Mil)43.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -2.95 -3.27 -3.80
EPS without NRI ($) -2.95 -3.27 -3.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GBT

Headlines

Articles On GuruFocus.com

More From Other Websites
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 22 2017
Market Is Home on the Range Again Mar 22 2017
Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion Mar 20 2017
GLOBAL BLOOD THERAPEUTICS, INC. Financials Mar 17 2017
5 Stocks The Best Performing Hedge Funds Are Piling Into Mar 16 2017
Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment Mar 16 2017
Coverage initiated on Global Blood Therapeutics by Cantor Fitzgerald Mar 16 2017
Global Blood reports 4Q loss Mar 13 2017
Global Blood reports 4Q loss Mar 13 2017
Market Takes 'National Napping Day' Seriously Mar 13 2017
GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 13 2017
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016... Mar 13 2017
Biotech Leads the Way Again Today Mar 13 2017
Late Market Rally but No Bounce for Bulls Mar 10 2017
Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of... Mar 10 2017
Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors Mar 10 2017
Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning Mar 09 2017
Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT) Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)